Adenosine derived from ecto-nucleotidases in calcific aortic valve disease promotes mineralization through A2a adenosine receptor

被引:34
|
作者
Mahmut, Ablajan [1 ]
Boulanger, Marie-Chloe [1 ]
Bouchareb, Rihab [1 ]
Hadji, Fayez [1 ]
Mathieu, Patrick [1 ]
机构
[1] Univ Laval, Dept Surg, Quebec Heart & Lung Inst, Res Ctr,LEMV,GRV, Ste Foy, PQ G1V 4G5, Canada
关键词
Calcific aortic valve disease; Calcific aortic valve stenosis; Aortic stenosis; Biomineralization; NPP1; ENPP1; 5 '-nucleotidase; NT5E; CD73; Ectopic mineralization; PKA; CREB; Adenosine; A2a receptor; POSTERIOR LONGITUDINAL LIGAMENT; INTERSTITIAL-CELLS; MOUSE MODEL; EXPRESSION; ECTO-5'-NUCLEOTIDASE; ATHEROSCLEROSIS; INACTIVATION; OSSIFICATION; PREVENTS; TARGET;
D O I
10.1093/cvr/cvv027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims In this study, we sought to determine the role of ecto-nucleotidases and adenosine receptors in calcific aortic valve disease (CAVD). The expression of ecto-nucleotidases, which modify the levels of extracellular nucleotides/nucleosides, may control the mineralization of valve interstitial cells (VICs). We hypothesized that expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), which generates AMP, and 5'-nucleotidase (CD73), an enzyme using AMP as a substrate to produce adenosine, may co-regulate the mineralization of the aortic valve. Methods and results We have investigated the expression of NPP1 and 5'-nucleotidase in CAVD tissues and determined the role of these ecto-nucleotidases on the mineralization of isolated VICs. In CAVD tissues (stenotic and sclerotic), we documented that NPP1 and 5'-nucleotidase were overexpressed by VICs. In isolated VICs, we found that mineralization induced by adenosine triphosphate was decreased by silencing NPP1 and 5'-nucleotidase, suggesting a role for adenosine. Adenosine and specific A2a adenosine receptor (A2aR) agonist increased the mineralization of VICs. Silencing of A2aR in human VICs and the use of A2aR(-/-) mouse VICs confirmed that A2aR promotes the mineralization of cells. Also, A2aR-mediated mineralization was negated by the transfection of a mutant dominant-negative G alpha(s) vector. Through several lines of evidence, we next documented that adenosine stimulated the mineralization of VICs through a cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway, and found that CREB positively regulated the expression of NPP1 in a positive feedback loop by physically interacting with the promoter. Conclusion Expression of NPP1 and 5'-nucleotidase by VICs promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway.
引用
收藏
页码:109 / 120
页数:12
相关论文
共 50 条
  • [31] Oligomerization of the fifth transmembrane domain from the adenosine A2A receptor
    Thévenin, D
    Lazarova, T
    Roberts, MF
    Robinson, CR
    PROTEIN SCIENCE, 2005, 14 (08) : 2177 - 2186
  • [32] Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor
    Guo, Dong
    Pan, Albert C.
    Dror, Ron O.
    Mocking, Tamara
    Liu, Rongfang
    Heitman, Laura H.
    Shaw, David E.
    IJzerman, Adriaan P.
    MOLECULAR PHARMACOLOGY, 2016, 89 (05) : 485 - 491
  • [33] Lessons From the Development of New Adenosine A2A Receptor Agonists
    Udelson, James E.
    JACC-CARDIOVASCULAR IMAGING, 2008, 1 (03) : 317 - 320
  • [34] A2A adenosine receptors in the CNS and Parkinson's disease:: Insights from the A2A receptor knockout mouse model
    Chen, JF
    Schwarzschild, MA
    DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 549 - 549
  • [35] Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?
    Jost, Wolfgang H.
    Toenges, Lars
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (12) : 565 - 570
  • [36] Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists
    Szabo, Nikoletta
    Kincses, Zsigmond Tamas
    Vecsei, Laszlo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (04) : 441 - 455
  • [37] A2A adenosine receptor antagonists -: future drugs for Parkinson's disease?
    Müller, CE
    DRUGS OF THE FUTURE, 2000, 25 (10) : 1043 - 1052
  • [38] Adenosine A2A receptor antagonists in Parkinson's disease: still in the running
    Antonini, Angelo
    Poewe, Werner
    LANCET NEUROLOGY, 2014, 13 (08): : 748 - 749
  • [39] Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
    Xu, K
    Bastia, E
    Schwarzschild, M
    PHARMACOLOGY & THERAPEUTICS, 2005, 105 (03) : 267 - 310
  • [40] Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
    Pinna, Annalisa
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1619 - 1631